Does My Patient Need an Advance Beneficiary Notice (ABN)?

FOR MEDICARE® PATIENTS WITH SOLID TUMORS

The decision tree should be applied independently for each primary cancer for which a patient has a diagnosis.

1. Are you the treating physician† and is the patient seeking further treatment?
   - **NO**
   - **YES**

2. What test are you ordering?
   - *IHC ordered as a stand-alone test does NOT require an ABN*
   - Multiple Tests
   - FoundationOne®Liquid CDx or FoundationOne®CDx
   - FoundationOne®Heme

3. Has the patient had the same test previously?
   - **NO**
   - **YES**
     - **NO**
     - **YES**

4. Has this patient’s disease progressed?
   - **NO**
   - **YES**

5. Is this patient any of the following: recurrent, relapse, refractory, metastatic, advanced stage III or IV?
   - **NO**
   - **YES**

6. ABN is required for second test
   - Medicare does not cover more than one test ordered concurrently, please follow decision tree to determine if patient meets clinical criteria for primary test

---

† A "treating physician" is a physician, as defined in 81861(r) of the Social Security Act, who furnishes a consultation or treats a beneficiary for a specific medical problem, and who uses the results of a diagnostic test in the management of the beneficiary’s specific medical problem. More information is available at https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R80BP.pdf

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if available. For the complete label, including companion diagnostic indications and important risk information, please visit http://www.F1CDxLabel.com and http://www.F1LCDxLabel.com.